Status:
COMPLETED
A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin Study
Lead Sponsor:
Seagen Inc.
Collaborating Sponsors:
Millennium Pharmaceuticals, Inc.
Conditions:
Disease, Hodgkin
Lymphoma, Large-Cell, Anaplastic
Eligibility:
All Genders
6+ years
Phase:
PHASE2
Brief Summary
This is a multicenter, open-label study to evaluate the safety and efficacy of treatment with brentuximab vedotin (SGN-35) in patients who have previously participated in an brentuximab vedotin study.
Detailed Description
This is a multicenter, open-label study to evaluate single-agent brentuximab vedotin (SGN-35) treatment in patients who previously participated in a brentuximab vedotin study, including Studies SGN35-...
Eligibility Criteria
Inclusion
- Participated in a previous brentuximab vedotin study.
- CD30-positive hematologic malignancy.
- At a minimum, experienced clinical benefit in the prior brentuximab vedotin study. For retreatment, patients must have previously achieved either complete or partial remission with brentuximab vedotin and experienced disease progression after discontinuing the prior brentuximab vedotin study.
Exclusion
- Withdrew consent to participate in any prior brentuximab vedotin study.
Key Trial Info
Start Date :
July 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2013
Estimated Enrollment :
110 Patients enrolled
Trial Details
Trial ID
NCT00947856
Start Date
July 1 2009
End Date
March 1 2013
Last Update
February 2 2017
Active Locations (17)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Alabama at Birmingham
Birmingham, Alabama, United States, 35294-3300
2
City of Hope National Medical Center
Duarte, California, United States, 91010
3
Stanford Cancer Center
Stanford, California, United States, 94305
4
Colorado Blood Cancer Institute
Denver, Colorado, United States, 80218